Results 271 to 280 of about 365,877 (337)

Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single‐Center Retrospective Study

The Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for malignant melanoma (MM). However, given variable response rates and potential toxicities, identifying robust biomarkers is crucial. We investigated whether the modified Glasgow Prognostic Score (mGPS) predicts treatment efficacy and toxicity in Asian patients with
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara   +4 more
wiley   +1 more source

Identification of altered immune landscape at single-cell resolution in NSCLC brain metastasis and its association with poor immune checkpoint inhibitor responses. [PDF]

Nat Commun
Bai M, Yin T, Li X, Wang P, Lei T, Jin P, Li F, Guo H, Guo X, Sun X, Li Y, Zou B, Yu J, Liu C, Teng F.   +14 more
europepmc   +1 more source

Viewpoint: Optimising Cancer Treatment to Reduce Its Environmental Impact

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT It is widely accepted that treatment and care for patients with cancer must and should happen, as it is what everyone would want for themselves and their loved ones. Everyone wants the best possible care, but climate change and the extreme weather that it causes are increasingly affecting everyone including patients in negative ways.
Robert Chuter, Kari Tanderup
wiley   +1 more source

RORγ drives non-small cell lung cancer progression by upregulating the NGF signaling. [PDF]

Respir Res
Zeng Y, Cai G, Zhang J, Zhang Z, Yin W, Ou T, Xu M, Li J, Kang Z, Bu J, Wang J, Huang J, Feng W.   +12 more
europepmc   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

PRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer. [PDF]

Clin Exp Med
Wang Y, Zhang M, Fang L, Qu J, Huo C, Li R, Yao J, Qu Y.   +7 more
europepmc   +1 more source

Real‐World Survival Outcomes in EGFR‐Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single‐Center Clinical Data Warehouse Analysis in South Korea

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective cohort study was conducted using clinical data derived from a single‐center clinical data warehouse (CDW). In Korean patients with EGFR‐mutant advanced NSCLC, first‐line treatment with 3G EGFR TKIs (osimertinib or lazertinib) demonstrated significantly better overall survival than 1G or 2G agents.
Bomi Kim, Sunghoon Kang, Iksoo Huh, Hyeoneui Kim   +3 more
wiley   +1 more source

Application of a predictive model for postoperative pulmonary complications in patients with non-small cell lung cancer based on cardiopulmonary exercise testing. [PDF]

J Thorac Dis
Li J, Wang XY, Wang MY, Ren MY, Li YQ, Jiang XW, Zhang M, Jiang ZL.   +7 more
europepmc   +1 more source